Gene editing refers to techniques that allow researchers to modify the DNA of various organisms. Given that it offers the potential to help discover innovative therapies, it isn't surprising that more and more drugmakers are turning to the technology.

Two prominent biotechs that focus on gene editing are CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). While both stocks have lagged the market recently, there's substantial upside potential for these innovative biotechs.

But which one is a better long-term investment? Let's dig in and find out.

Continue reading

Source Fool.com